Profile
Sector:
HealthcareCountry:
United KingdomIPO:
25 May 2018Website:
http://www.kiniksa.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 23:12:45 GMTDividend
Analysts recommendations
Institutional Ownership
KNSA Latest News
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Liisa Bayko - Evercore ISI Paul Choi - Goldman Sachs Eva Fortea-Verdejo - Wells Fargo David Nierengarten - Wedbush Securities Anupam Rama - JPMorgan Operator Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Third Quarter 2024 Earnings Conference Call.
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.01.
– ARCALYST ® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY ® Award-winning singer-songwriter, Carly Pearce – – Kiniksa expects to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors?
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09.
– Abiprubart Phase 2b clinical trial in Sjögren's Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations –
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will hold a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to discuss its first quarter 2024 financial results and recent portfolio execution.
- 1(current)
What type of business is Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
What sector is Kiniksa Pharmaceuticals in?
Kiniksa Pharmaceuticals is in the Healthcare sector
What industry is Kiniksa Pharmaceuticals in?
Kiniksa Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Kiniksa Pharmaceuticals from?
Kiniksa Pharmaceuticals is headquartered in United Kingdom
When did Kiniksa Pharmaceuticals go public?
Kiniksa Pharmaceuticals initial public offering (IPO) was on 25 May 2018
What is Kiniksa Pharmaceuticals website?
https://www.kiniksa.com
Is Kiniksa Pharmaceuticals in the S&P 500?
No, Kiniksa Pharmaceuticals is not included in the S&P 500 index
Is Kiniksa Pharmaceuticals in the NASDAQ 100?
No, Kiniksa Pharmaceuticals is not included in the NASDAQ 100 index
Is Kiniksa Pharmaceuticals in the Dow Jones?
No, Kiniksa Pharmaceuticals is not included in the Dow Jones index
When was Kiniksa Pharmaceuticals the previous earnings report?
No data
When does Kiniksa Pharmaceuticals earnings report?
The next expected earnings date for Kiniksa Pharmaceuticals is 28 February 2025